Eli Lilly Aktie - LLY

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Premium

Current Price

32,18

Gebot

31,13

Fragen

34,00

Volumen

65.286

33,46 Tagesbereich 33,46

0,00 52-Wochen-Bereich 0,00

Handelsende

33,84

Handelsbeginn

33,46

Letzte Trade

32.18

Letzter Handelszeitpunkt

Durchschnittliches Volumen (3 Mio.)

Finanzvolumen

VWAP

Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study

Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase...

Form PRE 14A - Other preliminary proxy statements

Lilly's EBGLYSS® (lebrikizumab-lbkz) single monthly maintenance injection achieved completely clear skin at three years in half of patients with moderate-to-severe atopic dermatitis

Lilly's EBGLYSS® (lebrikizumab-lbkz) single monthly maintenance injection achieved completely clear skin at...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Lilly to participate in Leerink Partners Global Healthcare Conference

Lilly to participate in Leerink Partners Global Healthcare Conference PR Newswire INDIANAPOLIS, Feb. 28, 2025...

Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) previously treated with a BTK inhibitor

Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with...

Form 4 - Statement of changes in beneficial ownership of securities

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

LLY - Frequently Asked Questions (FAQ)

What is the current Eli Lilly share price?

The current share price of Eli Lilly is $ 32,18

What is the 1 year trading range for Eli Lilly share price?

Eli Lilly has traded in the range of $ 0,00 to $ 0,00 during the past year

Volumen
% Tops
% Flops

Symbol	Preis	Vol.
CDMNCanadian Manganese Company Inc	$ 0,025 (25,00%)	173k
IFSSInterfield Global Software Inc	$ 0,065 (8,33%)	1.000
JETGlobal Crossing Airlines Group Inc	$ 0,85 (3,66%)	24,8k
VERSVerses AI Inc	$ 1,31 (3,15%)	326,14k
DEFIValour Inc	$ 3,47 (2,66%)	970,84k
NTDONintendo CDR	10,74 (-7,09%)	1,4k
JET.BGlobal Crossing Airlines Group Inc	$ 0,87 (-5,43%)	10,89k
ZEFIZefiro Methane Corp	$ 0,43 (-4,44%)	49k
HOLDImmutable Holdings Inc	$ 0,125 (-3,85%)	44,45k
HNDAHonda CDR	9,79 (-1,21%)	500
DEFIValour Inc	$ 3,47 (2,66%)	970,84k
MLMMcfarlane Lake Mining Limited	$ 0,05 (0,00%)	631k
FCGSFidelity Global Small Cap Opportunities Fund	$ 14,98 (0,00%)	416,29k
VERSVerses AI Inc	$ 1,31 (3,15%)	326,14k
ALGOLight AI Inc	0,64 (0,00%)	305,78k

Foren

Foren anzeigen

Keine Diskussionen Gefunden.

Neuen Thread Erstellen

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Eli Lilly and Company (LLY)

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Wichtige Statistiken und Details

LLY Neueste Nachrichten

Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study

Form PRE 14A - Other preliminary proxy statements

Lilly's EBGLYSS® (lebrikizumab-lbkz) single monthly maintenance injection achieved completely clear skin at three years in half of patients with moderate-to-severe atopic dermatitis

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Lilly to participate in Leerink Partners Global Healthcare Conference

Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) previously treated with a BTK inhibitor

Form 4 - Statement of changes in beneficial ownership of securities

Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study

Form PRE 14A - Other preliminary proxy statements

Lilly's EBGLYSS® (lebrikizumab-lbkz) single monthly maintenance injection achieved completely clear skin at three years in half of patients with moderate-to-severe atopic dermatitis

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Lilly to participate in Leerink Partners Global Healthcare Conference

LLY - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR

Trends

Toplisten

Marktdaten

News

Werkzeuge

Märkte

Entdecken

Hot Features

Follow Feed

Optionen-Flow

Watchlist

Eli Lilly and Company (LLY) Börsenkurse

Eli Lilly and Company (LLY)

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Wichtige Statistiken und Details

LLY Neueste Nachrichten

Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study

Form PRE 14A - Other preliminary proxy statements

Lilly's EBGLYSS® (lebrikizumab-lbkz) single monthly maintenance injection achieved completely clear skin at three years in half of patients with moderate-to-severe atopic dermatitis

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Lilly to participate in Leerink Partners Global Healthcare Conference

Lilly's Jaypirca (pirtobrutinib) recommended by CHMP for approval in the European Union for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) previously treated with a BTK inhibitor

Form 4 - Statement of changes in beneficial ownership of securities

Lilly's baricitinib delivered high rates of hair regrowth for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS study

Form PRE 14A - Other preliminary proxy statements

Lilly's EBGLYSS® (lebrikizumab-lbkz) single monthly maintenance injection achieved completely clear skin at three years in half of patients with moderate-to-severe atopic dermatitis

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Lilly to participate in Leerink Partners Global Healthcare Conference

LLY - Frequently Asked Questions (FAQ)

Beweger

Foren

Kürzlich von Ihnen besucht

Unternehmen

Geschäft

Popular

App herunterladen

Werbung entfernen

Zeitraum †	Änderung	Änderung %	Handelsbeginn	Hoch	Niedrig	Durchsch. Volumen	VWAP
1	0	0	0	0	0	0	0	DR
4	0	0	0	0	0	0	0	DR
12	0	0	0	0	0	0	0	DR
26	0	0	0	0	0	0	0	DR
52	0	0	0	0	0	0	0	DR
156	0	0	0	0	0	0	0	DR
260	0	0	0	0	0	0	0	DR